Literature DB >> 9326631

Functional association between promoter structure and transcript alternative splicing.

P Cramer1, C G Pesce, F E Baralle, A R Kornblihtt.   

Abstract

It has been assumed that constitutive and regulated splicing of RNA polymerase II transcripts depends exclusively on signals present in the RNA molecule. Here we show that changes in promoter structure strongly affect splice site selection. We investigated the splicing of the ED I exon, which encodes a facultative type III repeat of fibronectin, whose inclusion is regulated during development and in proliferative processes. We used an alternative splicing assay combined with promoter swapping to demonstrate that the extent of ED I splicing is dependent on the promoter structure from which the transcript originated and that this regulation is independent of the promoter strength. Thus, these results provide the first evidence for coupling between alternative splicing and promoter-specific transcription, which agrees with recent cytological and biochemical evidence of coordination between splicing and transcription.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326631      PMCID: PMC23504          DOI: 10.1073/pnas.94.21.11456

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins.

Authors:  A Yuryev; M Patturajan; Y Litingtung; R V Joshi; C Gentile; M Gebara; J L Corden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Signal transduction and transcriptional regulation by glucocorticoid receptor-LexA fusion proteins.

Authors:  P J Godowski; D Picard; K R Yamamoto
Journal:  Science       Date:  1988-08-12       Impact factor: 47.728

3.  A kinase-deficient transcription factor TFIIH is functional in basal and activated transcription.

Authors:  T P Mäkelä; J D Parvin; J Kim; L J Huber; P A Sharp; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

4.  The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements.

Authors:  G W Hunninghake; M M Monick; B Liu; M F Stinski
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

5.  Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.

Authors:  J F Cáceres; S Stamm; D M Helfman; A R Krainer
Journal:  Science       Date:  1994-09-16       Impact factor: 47.728

6.  A novel bipartite splicing enhancer modulates the differential processing of the human fibronectin EDA exon.

Authors:  M Caputi; G Casari; S Guenzi; R Tagliabue; A Sidoli; C A Melo; F E Baralle
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

7.  Higher level organization of individual gene transcription and RNA splicing.

Authors:  Y Xing; C V Johnson; P R Dobner; J B Lawrence
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

8.  Developmentally regulated alternative splicing of transcripts from the Drosophila homeotic gene Antennapedia can produce four different proteins.

Authors:  J R Bermingham; M P Scott
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

9.  The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities.

Authors:  R Tacke; J L Manley
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

10.  Human fibronectin: molecular cloning evidence for two mRNA species differing by an internal segment coding for a structural domain.

Authors:  A R Kornblihtt; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

View more
  133 in total

Review 1.  Chromatin modification by DNA tracking.

Authors:  A Travers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Spatial organization of RNA polymerase II transcription in the nucleus.

Authors:  M N Szentirmay; M Sawadogo
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

3.  Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform.

Authors:  J George; S S Wang; A M Sevcsik; M Sanicola; R L Cate; V E Koteliansky; D M Bissell
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Adeno-associated virus RNAs appear in a temporal order and their splicing is stimulated during coinfection with adenovirus.

Authors:  M B Mouw; D J Pintel
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Mature mRNAs accumulated in the nucleus are neither the molecules in transit to the cytoplasm nor constitute a stockpile for gene expression.

Authors:  D Weil; S Boutain; A Audibert; F Dautry
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

6.  Evolution of the RNA polymerase II C-terminal domain.

Authors:  John W Stiller; Benjamin D Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

7.  The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1.

Authors:  A C Goldstrohm; T R Albrecht; C Suñé; M T Bedford; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  The adeno-associated virus type 2 Rep protein regulates RNA processing via interaction with the transcription template.

Authors:  Jianming Qiu; David J Pintel
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

9.  Coupled in vitro synthesis and splicing of RNA polymerase II transcripts.

Authors:  S Ghosh; M A Garcia-Blanco
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

10.  Combinatorial control of a neuron-specific exon.

Authors:  E F Modafferi; D L Black
Journal:  RNA       Date:  1999-05       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.